Trimegestone(17
-methyl-17
-(2(
S)-hydroxy-1-oxopropyl)estra-4,9-dien-3-one) is a new progestomimetic moleculedeveloped by Roussel Uclaf for the treatment ofpostmenopausaldiseases. It is produced on an industrial scale from arelated3-ketal, 17-keto norsteroid intermediate in a nine-stepsequenceinvolving hydrocyanation of the 17-keto group, alkylationofthe protected cyanohydrin with ethyl magnesium bromide togive a 17
-hydroxy 20-ketone, stereospecific17
-methylationof the corresponding 17,20-enolate, and oxidation of the20,21-enolate with air and ketal deprotection to give3,20,21-triketone. The key step of the synthesis is the chemo-,regio-,and almost stereospecific bioreduction of this triketone tothedesired 21(
S) alcohol, Trimegestone (de = 99%).This bioreduction is performed with bakers' yeast in water, thusshowingthe efficiency of this method at an industrial level.